logo-loader
viewNuvo Pharmaceuticals Inc.

Full interview: Nuvo Pharmaceuticals subsidiary announces Takeda’s Cabpirin approved in Japan

Nuvo Pharmaceuticals (TSE: NRI- OTCQX: NRIFF) President and CEO Jesse Ledger joined Steve Darling from Proactive in Vancouver to discuss the company’s Nuvo Ireland announcing  Takeda Pharmaceutical has given notice  Japan's Ministry of Health, Labor and Welfare have approved Cabpirin combination tablets.

Ledger discusses what this means for the company and its revenue going forward. Ledger also told Proactive how the company is dealing with COVID-19 right now and in the future.

Quick facts: Nuvo Pharmaceuticals Inc.

Price: 0.79 CAD

TSX:NRI
Market: TSX
Market Cap: $9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

[email protected] Capital CEO discusses new Head of Enterprise Risk Management hire

[email protected] Capital PLC's (LON:SYME) Alessandro Zamboni speaks to Proactive following the announcement they've appointed Stuart Nelson as Head of Enterprise Risk Management (ERM). Zamboni says Nelson is a highly experienced credit analyst with experience assessing risk across multiple product...

41 minutes ago

2 min read